5 Stocks to Buy According to Stephen DuBois’ Camber Capital Management

In this article, we discuss 5 stocks to buy according to Stephen DuBois’ Camber Capital Management. If you want to read our detailed analysis of DuBois’ history, investment philosophy, and hedge fund performance, go directly to 10 Stocks to Buy According to Stephen DuBois’ Camber Capital Management.

5. Gilead Sciences, Inc. (NASDAQ:GILD)

Camber Capital Management’s Stake Value: $148,625,000
Percentage of Camber Capital Management’s Portfolio: 5.37%
Number of Hedge Fund Holders: 68

Gilead Sciences, Inc. (NASDAQ:GILD) is an American bio-pharmaceutical company researching and creating antiviral medications used to treat COVID-19, hepatitis B, hepatitis C, influenza, and HIV/AIDS. Those medications include ledipasvir/sofosbuvir.

On May 23, David Risinger, an analyst at SVB Leerink, initiated coverage of Gilead Sciences (NASDAQ:GILD), assigning a ‘Market Perform’ rating and a price objective of $68. Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital stood as the largest shareholder of Gilead Sciences (NASDAQ:GILD) in the first quarter, with a $1.07 billion stake representing a 325% increase in holding size over the previous quarter.

Gilead Sciences, Inc. (NASDAQ:GILD) was in 68 hedge funds’ portfolios at the end of the first quarter of 2022, compared to 54 funds in the fourth quarter of 2021. Gilead Sciences, Inc. (NASDAQ:GILD) shares have lost 8.84% over the past 12 months as of July 4.

With an estimated net worth of $62.57 million, DuBois first picked up Gilead Sciences, Inc. (NASDAQ:GILD) for Camber Capital Management’s portfolio in the second quarter of 2016. The hedge fund increased its stake by 12% in Q1 to bring its total holding up to 2.50 million shares worth $149 million as of March 31.

In its Q4 2021 investor letter, ClearBridge Investments mentioned Gilead Sciences, Inc. (NASDAQ:GILD). Here is what the firm said:

“Other pharma companies are providing solutions as well. Biopharmaceutical company Gilead Sciences’ remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication administered by intravenous infusion; it can shorten the time to recovery in hospitalized patients and reduce the risk of hospitalization and death in non-hospitalized patients.”